Inspire Investing LLC Takes $967,000 Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Inspire Investing LLC has acquired a new stake of 15,147 shares in Sarepta Therapeutics, valued at approximately $967,000, indicating growing institutional interest in the biotechnology firm.
• Despite recent institutional investments, Sarepta Therapeutics faces mixed analyst sentiments, with ratings ranging from "Buy" to "Sell" and a significant reduction in price objectives from previous highs.
• The company reported a 68.4% increase in quarterly revenue year-over-year, reaching $611.09 million, significantly beating analysts' expectations.

Inspire Investing LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 15,147 shares of the biotechnology company's stock, valued at approximately $967,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after purchasing an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Sarepta Therapeutics by 2.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock worth $127,512,000 after acquiring an additional 41,408 shares during the last quarter. EcoR1 Capital LLC grew its stake in Sarepta Therapeutics by 67.8% during the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock valued at $82,480,000 after acquiring an additional 522,386 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Sarepta Therapeutics by 438.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after purchasing an additional 580,123 shares in the last quarter. Finally, Aberdeen Group plc boosted its holdings in shares of Sarepta Therapeutics by 42.1% during the 1st quarter. Aberdeen Group plc now owns 650,279 shares of the biotechnology company's stock valued at $41,676,000 after purchasing an additional 192,584 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Trading Up 5.8%

NASDAQ SRPT traded up $1.00 on Thursday, hitting $18.05. 3,953,772 shares of the stock were exchanged, compared to its average volume of 6,321,412. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The firm has a market capitalization of $1.76 billion, a P/E ratio of -20.71 and a beta of 0.49. The stock has a fifty day moving average price of $17.69 and a two-hundred day moving average price of $39.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same quarter last year, the business earned $0.07 EPS. The business's revenue was up 68.4% on a year-over-year basis. Research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of research reports. Barclays raised Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 price target for the company in a research note on Tuesday, July 29th. The Goldman Sachs Group upped their price objective on Sarepta Therapeutics to $19.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Royal Bank Of Canada lowered their target price on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research report on Thursday, July 17th. Guggenheim restated a "buy" rating and issued a $22.00 price target on shares of Sarepta Therapeutics in a research report on Monday. Finally, BMO Capital Markets upped their price target on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a research note on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $39.32.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.